Syros Pharmaceuticals, Inc. (SYRS)
| Market Cap | 61.42M |
| Revenue (ttm) | 24.13M |
| Net Income (ttm) | -97.48M |
| Shares Out | 62.99M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 625,285 |
| Open | 0.890 |
| Previous Close | 0.900 |
| Day's Range | 0.890 - 0.980 |
| 52-Week Range | 0.650 - 5.640 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 9.79 (+904.0%) |
| Earnings Date | Aug 9, 2022 |
About SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute... [Read more...]
Financial Performance
In 2021, SYRS's revenue was $23.49 million, an increase of 55.62% compared to the previous year's $15.09 million. Losses were -$86.56 million, 3.00% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for SYRS stock is "Buy." The 12-month stock price forecast is 9.79, which is an increase of 904.00% from the latest price.
News
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of a restricted stock un...
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for th...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency ...
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
Syros Pharmaceuticals, Inc. (SYRS) Moves to Strong Buy: Rationale Behind the Upgrade
Syros Pharmaceuticals, Inc. (SYRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - July 6, 2022) - Rigrodsky Law, P.A. is investigating Tyme Technologies, Inc. ("Tyme") (NASDAQ: TYME) regarding possible breaches of fiduciary duties and other vio...
SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.
NEW YORK , July 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals, Inc. ("Syros" or th...
TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Ade...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies,...
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expenses c...
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
CAMBRIDGE, Mass. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NAS...
Syros to Present at JMP Securities Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...
Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, includin...
Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR)...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data from our CDK12...
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...
Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Mil...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter an...
Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference...
Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclinica...
Syros to Participate in Upcoming Virtual Investor Conferences in March
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Adminis...
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Co...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical developmen...
Syros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, N...
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.65% and 11.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the ...
Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter en...